ライフサイエンスコーパス: adrenocortical carcinoma

1 HGF/cMET expression and cancer hallmarks of adrenocortical carcinoma.

2 vestigate efficacy in patients with advanced adrenocortical carcinoma.

3 dualised and improved therapeutic options in adrenocortical carcinoma.

4 survival in patients with radically resected adrenocortical carcinoma.

5 velop gonadal tumors and-when gonadectomized-adrenocortical carcinoma.

6 mg/m2 had improvement in liver metastases of adrenocortical carcinoma.

7 nces in understanding the molecular basis of adrenocortical carcinoma.

8 s positively with survival for patients with adrenocortical carcinoma.

9 Mitotane is the only approved therapy for adrenocortical carcinoma.

10 le of cabozantinib in patients with advanced adrenocortical carcinoma.

11 There were no occult adrenocortical carcinomas.

12 's sarcomas, gliomas, rhabdomyosarcomas, and adrenocortical carcinomas.

13 ession was associated with worse survival in adrenocortical carcinoma (-1757 days, p < 0.001) and eso

14 To gain insight into the pathogenesis of adrenocortical carcinoma (ACC) and whether there is prog

15 Adrenocortical carcinoma (ACC) has a poor prognosis, and

16 nalyze the incidence of and risk factors for adrenocortical carcinoma (ACC) in adrenal incidentaloma

17 utant, R337H (p53tet-R337H), associated with adrenocortical carcinoma (ACC) in children, can be conve

18 Adrenocortical carcinoma (ACC) is a rare aggressive pedi

19 Adrenocortical carcinoma (ACC) is a rare and aggressive

20 Adrenocortical carcinoma (ACC) is a rare but aggressive

21 Adrenocortical carcinoma (ACC) is a rare cancer in which

22 Adrenocortical Carcinoma (ACC) is a rare endocrine tumor

23 Adrenocortical carcinoma (ACC) is a rare malignancy with

24 Adrenocortical carcinoma (ACC) is a rare pediatric malig

25 Adrenocortical carcinoma (ACC) is an endocrine malignanc

26 pathway activity lead to poorer prognosis in adrenocortical carcinoma (ACC) patients.

27 ng could expose novel targets for therapy in adrenocortical carcinoma (ACC), a rare and lethal cancer

28 including small cell lung cancer (SCLC) and adrenocortical carcinoma (ACC), a rare cancer with few e

29 tudy, we investigated the role of RARRES2 in adrenocortical carcinoma (ACC), a rare lethal malignancy

30 a comprehensive genomic characterization of adrenocortical carcinoma (ACC).

31 mplicated in sporadic and syndromic forms of adrenocortical carcinoma (ACC).

32 ily member with a sarcoma, breast, brain, or adrenocortical carcinoma (ACC).

33 ts who underwent curative intent surgery for adrenocortical carcinoma (ACC).

34 Adrenocortical carcinomas (ACC) are rare and aggressive

35 The results show that adrenocortical carcinomas (ACC) have relatively sarcopen

36 s pheochromocytomas, paragangliomas, and the adrenocortical carcinomas (ACC), adenomas (ACA), and hyp

37 spectrum was characterized by osteosarcomas, adrenocortical carcinomas (ACC), CNS tumors, and soft ti

38 Adrenocortical carcinomas (ACCs) are rare and highly mal

39 we generated transcriptional profiles of 11 adrenocortical carcinomas (ACCs), 4 adrenocortical adeno

40 ad partial responses (two patients each with adrenocortical carcinoma and mesothelioma, and one patie

41 relative to general population rates were in adrenocortical carcinoma and phyllodes tumour.

42 rozygosity in Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast

43 eukemia, melanoma, duodenal adenocarninomas, adrenocortical carcinomas, and neuroblastomas.

44 series examines the presence of necrosis in adrenocortical carcinoma as a diagnostic and prognostic

45 uence level, is required to fully understand adrenocortical carcinoma biology and apply that knowledg

46 ecent advances that promise to shed light on adrenocortical carcinoma biology.

47 and muscle, but expression in human NCI-H295 adrenocortical carcinoma cells is initiated by two other

48 Finally, our data from NCI-H295R adrenocortical carcinoma cells suggest that adrenocortic

49 Accordingly, treatment of adrenocortical carcinoma cells with exogenous HGF result

50 increased progesterone (P4up) in human H295R adrenocortical carcinoma cells, an OECD validated assay

51 rom ~1,800 chemicals screened in H295R human adrenocortical carcinoma cells.

52 been the mainstay for primary and recurrent adrenocortical carcinoma due to the lack of effective ad

53 previous systemic cytotoxic chemotherapy for adrenocortical carcinoma, Eastern Cooperative Oncology G

54 an important role for HGF/cMET signaling in adrenocortical carcinoma growth and resistance to common

55 ation of the involvement of BMP signaling in adrenocortical carcinoma growth regulation, and the disc

56 The molecular characterization of adrenocortical carcinoma has identified dysregulation of

57 esistance to chemotherapy, but their role in adrenocortical carcinoma has not been examined.

58 No significant advances in the treatment of adrenocortical carcinoma have been developed.

59 ent studies focusing on the tumorigenesis of adrenocortical carcinoma have focused on onco-developmen

60 n associations including germline TP53 PV in adrenocortical carcinoma, high-grade glioma (HGG), and m

61 The genetic events associated with adrenocortical carcinoma in adults are distinct from tho

62 Adrenocortical carcinoma is a rare cancer that has a poo

63 Adrenocortical carcinoma is a rare malignancy with an an

64 Paediatric adrenocortical carcinoma is a rare malignancy with poor

65 Adrenocortical carcinoma is a rare malignancy with poor

66 Adrenocortical carcinoma is a rare malignancy with poor

67 Adrenocortical carcinoma is a rare malignancy, accountin

68 Adrenocortical carcinoma is a rare neoplasm characterize

69 Adrenocortical carcinoma is a rare, aggressive cancer fo

70 Adrenocortical carcinoma is an aggressive, lethal malign

71 d nonfunctional tumors larger than 4 cm when adrenocortical carcinoma is not suspected.

72 Although adrenocortical carcinoma is rare, such rare cancers acco

73 at instead of treatment with mitotane, human adrenocortical carcinomas may be much more sensitive to

74 ly older (P=0.03) and had more stage I or II adrenocortical carcinomas (P=0.02) than did patients in

75 Pediatric adrenocortical carcinoma (pACC) is a rare and aggressive

76 rable progress has occurred in understanding adrenocortical carcinoma pathogenesis from the study of

77 A child with Down syndrome and a history of adrenocortical carcinoma resected at age 1 year presente

78 that increased HGF/cMET expression in human adrenocortical carcinoma samples was positively associat

79 Cabozantinib in advanced adrenocortical carcinoma showed promising efficacy with

80 In adult primary adrenocortical carcinoma, the main somatic genetic alter

81 randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either

82 ult patients (aged >=18 years) with advanced adrenocortical carcinoma was done at the University of T

83 lly confirmed locally advanced or metastatic adrenocortical carcinoma were recruited at clinical site

84 Images of 24 adrenocortical carcinomas were also reviewed to determin

85 In addition, pediatric adrenocortical carcinomas were found to share similar pa

86 nal tumors (16 adenomas, six metastases, one adrenocortical carcinoma) were reviewed.

87 igible patients had histologically confirmed adrenocortical carcinoma, were not candidates for surger

88 se recent translational research advances in adrenocortical carcinoma, which it is hoped could lead t

89 Recently, integrated molecular studies of adrenocortical carcinomas, which have characterized soma

90 issue sarcomas, osteosarcoma, brain tumours, adrenocortical carcinoma, Wilms' tumour and phyllodes tu

91 noviral vectors suitable for gene therapy of adrenocortical carcinomas with poor prognosis.

92 gamut of clinical presentations, as well as adrenocortical carcinoma, with its advanced disease at p